Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

836.11 +3.52 (+0.42%)
Streaming Delayed Price Updated: 12:35 PM EDT, Jun 5, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,118,852
Open 830.49
Bid (Size) 835.70 (4)
Ask (Size) 836.42 (2)
Prev. Close 832.59
Today's Range 817.62 - 836.26
52wk Range 432.34 - 838.28
Shares Outstanding N/A
Dividend Yield 0.54%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
British Agency Supports Eli Lilly's Weight Loss Drug Mounjaro, Diverging From Restrictions on Rival Novo Nordisk's Wegovy
NICE recommends Eli Lilly's Mounjaro for obesity, omitting time limits applied to Novo Nordisk's Wegovy, opening new avenues for long-term treatment. 
Via Benzinga
Google Parent Alphabet Appoints Eli Lilly's Finance Chief Ashkenazi As CFO
Anat Ashkenazi resigns as CFO of Eli Lilly to join Google as CFO and SVP. She will remain at Lilly until July 2024 while her successor is sought. 
Via Benzinga

Performance

YTD
+41.19%
+41.19%
1 Month
+9.06%
+9.06%
3 Month
+7.53%
+7.53%
6 Month
+42.16%
+42.16%
1 Year
+88.20%
+88.20%

More News

Read More
Madrigal, Akero, 89bio Tumble After Lilly's Weight-Loss Drug Tackles MASH
Via Investor's Business Daily
Alphabet Picks Eli Lilly Executive Anat Ashkenazi As New CFO
Via Investor's Business Daily
AMZN Buy Alert: Why Amazon Stock Is a Bargain Hiding in Plain Sight
Via InvestorPlace
If You Invested $100 In This Stock 5 Years Ago, You Would Have $700 Today
Via Benzinga
Eli Lilly and Co's Options: A Look at What the Big Money is Thinking
Via Benzinga
Performance Comparison: Eli Lilly and Co And Competitors In Pharmaceuticals Industry
Via Benzinga
Large Cap BIopharmaceuticals Overview
Via Talk Markets
Topics Stocks
Exposures US Equities
Structure Therapeutics' Obesity Candidate Is ' Very Competitive' To Eli Lilly's Orforglipron, Analyst Says
Via Benzinga
Eli Lilly Beefs Up Neuro Pipeline With Addition Of Preclinical ALS, Dementia Prospect
Via Benzinga
Structure Therapeutics Stock Skyrockets To Six-Month High On Compelling Weight-Loss Drug Results
Via Investor's Business Daily
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Watch Out Wegovy: Here Comes Another Promising Anti-Obesity Candidate
Via The Motley Fool
Hims & Hers Health Soars on Generic GLP-1 Rollout Plans
Via MarketBeat
4 Stocks Making New Highs Despite Market Weakness
Via MarketBeat
The Week Ahead: What's Next
Via Talk Markets
Prediction: These Could Be the Best-Performing Pharmaceutical Stocks Through 2030
Via The Motley Fool
This Is the Biggest Risk for Eli Lilly and Novo Nordisk Investors
Via The Motley Fool
S&P 500 Giants Lead Five Healthy Stocks Near Buy Points
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Novo Nordisk Sues Additional US Clinics Against Fake Semaglutide Products Used For Weight Loss, Diabetes
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Unearthing Unknown Stocks: 3 Picks That Could Be the Next Big Thing
Via InvestorPlace
Aristocrats in Disguise: 3 Blue-Chip Stocks With Stealth Growth Potential
Via InvestorPlace
Institutional Bets: 7 Stocks the Big Money Will Send Higher This Year
Via InvestorPlace
New Weight Loss ETF Is Essentially A Play On Eli Lilly, Novo Nordisk
Via Benzinga
Topics ETFs
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.